Barrow, Hanley, Mewhinney & Strauss’s PDL BioPharma, Inc. PDLI Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-23,201	Closed	-$79K	–	455
2017 Q3	$79K	Sell	23,201 -2,186	-9%	-$6.08K	﹤0.01%	348
2017 Q2	$63K	Hold	25,387	–	–	﹤0.01%	359
2017 Q1	$58K	Sell	25,387 -272,239	-91%	-$602K	﹤0.01%	359
2016 Q4	$631K	Sell	297,626 -1,659	-0.6%	-$4.63K	﹤0.01%	323
2016 Q3	$1M	Buy	299,285 +2,110	+0.7%	+$6.7K	﹤0.01%	294
2016 Q2	$933K	Sell	297,175 -1,068	-0.4%	-$3.56K	﹤0.01%	288
2016 Q1	$993K	Buy	298,243 +16,497	+6%	+$51.4K	﹤0.01%	291
2015 Q4	$997K	Buy	281,746 +5,255	+2%	+$22K	﹤0.01%	288
2015 Q3	$1.39M	Hold	276,491	–	–	﹤0.01%	269
2015 Q2	$1.78M	Buy	276,491 +14,192	+5%	+$95.1K	﹤0.01%	256
2015 Q1	$1.84M	Buy	+262,299	New	+$1.9M	﹤0.01%	246

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's PDLI Position: Q4 2017 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of PDL BioPharma, Inc. (PDLI) in Q4 2017, closing a stake of 23,201 shares — an estimated $79K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in PDLI in Q1 2015 and held it in 11 quarters. The position peaked at $1.84M in Q1 2015. 187 funds tracked by Wall St. Rank hold PDLI as of Q4 2017.

Barrow, Hanley, Mewhinney & Strauss reported no remaining PDL BioPharma, Inc. position as of Q4 2017 after selling out during the quarter.
Barrow, Hanley, Mewhinney & Strauss sold 23,201 PDL BioPharma, Inc. shares in Q4 2017, an estimated $79K.
Barrow, Hanley, Mewhinney & Strauss first reported a position in PDL BioPharma, Inc. in Q1 2015 and held it in 11 quarters.
Barrow, Hanley, Mewhinney & Strauss's PDL BioPharma, Inc. position peaked at $1.84M in Q1 2015.
187 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2017.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q4 2017, filed 9 Feb 2018.